Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

Rhea-AI Summary

Design Therapeutics (NASDAQ: DSGN), a clinical-stage biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York. Interested parties can access a live webcast of the presentation through the company's website or the provided link, with the recording remaining available for at least 30 days after the event.

News Market Reaction – DSGN

+3.09%

+3.09% Session move

In the trading session that priced this news, DSGN gained 3.09%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York.

A live webcast of the presentation will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.

About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC^® gene targeted chimera small molecules. The company’s GeneTAC^® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC^® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

FAQ

When is Design Therapeutics (DSGN) presenting at the 2025 Jefferies Healthcare Conference?

Design Therapeutics will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m. ET in New York.

How can I watch Design Therapeutics' (DSGN) presentation at the Jefferies Conference?

The presentation can be accessed via live webcast through the investors section of Design Therapeutics' website (www.designtx.com) or through the provided link.

How long will Design Therapeutics' (DSGN) Jefferies Conference presentation be available to view?

The webcast will be archived and available for viewing for at least 30 days following the presentation.

What type of company is Design Therapeutics (DSGN)?

Design Therapeutics is a clinical-stage biotechnology company that develops treatments for serious degenerative genetic diseases.